Clinical Trial

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

The medical device firm reports 20% Q1 revenue growth, fueled by new billing codes that boost Barostim approvals and a trial to triple its patient base.

A novel drug combination shows promising early results for a deadly ovarian cancer, potentially expanding the benefit of immunotherapy to more patients.

A new study shows the feasibility of a single device for glucose monitoring and insulin delivery, aiming to simplify life for millions with diabetes.

Backed by FDA approval and strong clinical data, EBR Systems' leadless WiSE pacer is set to transform cardiac therapy for previously untreatable patients.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

With the hire of a top scientist, a minority-owned IT firm signals its ambition to tackle complex federal health challenges and compete with industry giants.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

KingstronBio's successful implant of its advanced ProStyle M® heart valve kicks off a key study, signaling a new era for patients and China's medtech.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Following positive safety data, Phanes Therapeutics expands trials for spevatamig, a first-in-class antibody targeting two cancer pathways at once.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.